After years of financial struggles related to its mainstay product’s loss of exclusivity and multiple failures of R&D projects, Sumitomo Pharma is further pivoting toward its allogeneic induced pluripotent stem cell (iPSC) therapy business with a new joint venture.
Sumitomo In Cell Therapy Pivot With New JV, US Sales Push
Response To Ongoing Business Challenges?
The struggling Japanese pharma group is aiming to grow its new cell therapy business in the US and Japan to $2.3bn by the late 2030s.
